President Biden made big headlines by pardoning federal violations of simple cannabis possession, citing that “too many lives have been upended because of our failed approach to marijuana." But will the decision really move the needle? Scott Burris, Professor of Law at Temple University’s Beasley School of Law, examines the ripple effects of Biden’s announcement, and dives into the implications of how controlled substances, specifically marijuana, are scheduled by the federal government and states.
Approximately 3,000 state and local governments have sued opioid manufacturers and distributors to compensate for government opioid epidemic spending. These lawsuits have resulted in major structured settlements to certain states and local governments. Based in part on lack of restrictions on 1998 tobacco settlements state spending, which was often not targeted at tobacco control and cessation, national experts lead by the Legislative Analysis and Public Policy Association (LAPPA) partnered to develop model state legislation directing use of opioid litigation proceeds.
To mitigate morbidity and mortality associated with prescription opioids, most states have implemented limits on opioid analgesic prescribing. Approaches vary, but these laws generally restrict the duration of an opioid prescriptions by the number of days supplied. Some states additionally limit the daily dosage or total dosage allowed in opioid prescriptions.
This dataset presents state-level statutes and regulations across all 50 states and the District of Columbia in effect between January 1, 2014 and December 31, 2019.
This dataset, published on PDAPS.org, is cross-sectional and displays key features of state laws increasing access to buprenorphine and methadone during COVID-19 across all 50 states and the District of Columbia approved as of June 1, 2021.
This dataset, published on PDAPS.org, is cross-sectional and displays key features of mitigation laws at state correctional facilities relating to MOUD treatment across all 50 states and the District of Columbia in effect as of September 1, 2021.
This dataset, which is published to the Prescription Drug Abuse Policy System (PDAPS.org) is longitudinal and displays key features of state commercial insurance and Medicaid coverage laws related to medication for opioid use disorder (MOUD) across all 50 states and the District of Columbia, in effect between August 1, 2017 and August 1, 2020.
This dataset, which is published to the Prescription Drug Abuse Policy System (PDAPS.org), is cross-sectional and displays key features of licensing requirements related to medications for opioid use disorder (MOUD) treatment for facilities and providers across all 50 states and the District of Columbia in effect as of August 1, 2020.
Indiana University Robert H. McKinney School of Law
Medicaid is at the core of the opioid overdose epidemic. Both state and federal government reactions continue to shape the outcomes of this epidemic while death rates in some states continue to increase. There is a strong correlation between those suffering from opioid use disorder and those eligible for Medicaid. Most significantly, individuals with opioid use disorder enrolled in their state’s Medicaid program experience greater positive health outcomes compared to those without coverage.